These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26522694)

  • 1. Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials.
    Sun Z; Zhu Y; Xia J; Sawakami T; Kokudo N; Zhang N
    Biosci Trends; 2016 May; 10(2):85-91. PubMed ID: 26522694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.
    Hong Y; Peng Y; Guo ZS; Guevara-Patino J; Pang J; Butterfield LH; Mivechi NF; Munn DH; Bartlett DL; He Y
    Hepatology; 2014 Apr; 59(4):1448-58. PubMed ID: 24122861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
    Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
    Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
    Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
    Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress of alpha-fetoprotein vaccine in hepatocellular carcinoma].
    Cheng LL; Chen BD; Zhao GZ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Feb; 28(2):183-187. PubMed ID: 32164075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
    Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
    Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for successful vaccination against hepatocellular carcinoma.
    Rinaldi M; Iurescia S; Fioretti D; Ponzetto A; Carloni G
    Int J Immunopathol Pharmacol; 2009; 22(2):269-77. PubMed ID: 19505380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
    Schmidt N; Neumann-Haefelin C; Thimme R
    Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.
    He Y; Hong Y; Mizejewski GJ
    Immunotherapy; 2014; 6(6):725-36. PubMed ID: 25041030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer peptide vaccine targeted glypican-3 antigen].
    Nakatsura T
    Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in cancer vaccine development for hepatocellular carcinoma.
    Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of immunotherapy for hepatocellular carcinoma.
    Breous E; Thimme R
    J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
    Jiang Y; Han QJ; Zhang J
    World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Honda M; Arai K; Yamashita T; Nakamoto Y; Kaneko S
    J Hepatol; 2008 Dec; 49(6):946-54. PubMed ID: 18619700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein.
    Chou CK; Hung JY; Liu JC; Chen CT; Hung MC
    Cancer Gene Ther; 2006 Aug; 13(8):746-52. PubMed ID: 16410824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DNA vaccine encoding alpha-fetoprotein with fused ornithine decarboxylase degradation signal significantly suppresses hepatocellular carcinoma growth in mice].
    Morozov AV; Morozov VA; Astakhova TM; Timofeev AV; Karpov VL
    Mol Biol (Mosk); 2012; 46(3):434-51. PubMed ID: 22888633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.